<DOC>
	<DOCNO>NCT00432965</DOCNO>
	<brief_summary>To determine topical negative pressure therapy deliver V.A.C.® device clinically efficacious cost effective treatment diabetic foot ulcer . The purpose study compare effectiveness V.A.C.® Therapy moist wound therapy diabetic foot ulcer . The primary objective determine effect V.A.C.® Therapy incidence complete wound closure . Secondary objective include : evaluating acceleration ulcer closure facilitation surgical closure , reduction ulcer surface area time , reduction complication , quality life average total cost care .</brief_summary>
	<brief_title>Randomized , Controlled Multicenter Trial Vacuum Assisted Closure Therapy™ Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Presence calcaneal , dorsal plantar diabetic foot ulcer ≥ 2 cm2 area debridement . ( If one ulcer present , wound treat use method , one ulcer study . ) DFU equivalent Stage 2 great , define Wagner 's Scale system ( See Appendix E ) Evidence adequate perfusion one following affected extremity , ( within past 60 day ) : Dorsum transcutaneous oxygen test ( TcPO2 ) result ≥30 mmHg , ABIs result ≥0.7 ≤1.2 toe pressure result ≥30 mmHg , Doppler arterial waveform , triphasic biphasic ankle affect leg . Age ≥ 18 year age HbA1c ≤ 12 % ( collect within last 90 day . ) Evidence adequate nutrition one following : Lab result reflect PreAlbumin &gt; 16 mg/dl Albumin level &gt; 3 g/dl ( seven day prior study period ) , nutritional consult do appropriate supplementation start . Proper documentation CRFs need . Patients recognize active Charcot abnormality foot , evidence clinical symptom interfere either randomized treatment group Ulcers result electrical , chemical , radiation burn , venous insufficiency Untreated infection cellulites site target ulcer Presence untreated osteomyelitis Collagen vascular disease Malignancy ulcer Presence necrotic tissue Uncontrolled hyperglycemia Concomitant medication include ( washout period 30 day corticosteroid , immunosuppressive medication , chemotherapy ) Open amputation Prior V.A.C . therapy within 30 day . Current prior normothermic ( WarmUP® ) HBO therapy within 30 day . Current prior treatment recombinant autologous growth factor product within past 30 day . ( Examples : Regranex Procuren ) Current prior treatment skin dermal substitute dressing ( Examples : Apligraft , Dermagraft , Integra ) live cell capable produce growth factor ( Example : Oasis ) within past 30 day . Current use enzymatic debridment agent ( Example : Acuzyme /Panafil ) active treatment phase study Pregnant nursing mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Wound closure</keyword>
	<keyword>Accelerated healing</keyword>
</DOC>